GLPwatch
Wegovy for Cardiovascular risk reduction
semaglutide · FDA-approved
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is FDA-approved for reducing cardiovascular risk. Research, including the SELECT trial, shows semaglutide’s role in lowering cardiovascular risk in certain patients.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Cardiovascular risk reduction |
| Approval status | FDA-approved |
| Research papers | 50 |
Wegovy is FDA-approved for cardiovascular risk reduction. See the current label on the Wegovy page.
Research on semaglutide for cardiovascular risk reduction (50)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- The Discovery and Development of Liraglutide and Semaglutide.
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
- Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.
- Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
- Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
- Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
- Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
- Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
- Semaglutide: First Global Approval.